SCHEMBL19982578

SCHEMBL19982578

CCOP(=O)(Cc1ccc(COc2ccccc2CN2CCN(Cc3ccc4nc(-c5ccc(C(F)(F)F)cc5)[nH]c4c3)CC2)cc1)OCC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 2/20 0.45
KCNH2 Q12809 4/20 0.40
HDAC6 Q9UBN7 3/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
FGFR1 P11362 1/20 0.39
FLT1 P17948 1/20 0.39
DGAT1 O75907 3/20 0.39
NPBWR1 P48145 3/20 0.39
GNRHR P30968 2/20 0.38
TACR2 P21452 1/20 0.38
HRH2 P25021 1/20 0.38
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
MAOB P27338 1/20 0.38
SOAT1 P35610 2/20 0.37
PTGDR2 Q9Y5Y4 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19982561 0.95 SLC2A1 (0.46) SLC2A1KCNH2HDAC6HDAC3HDAC1
SCHEMBL19982610 0.93 SLC2A1 (0.42) SLC2A1KCNH2FGFR1FLT1NPBWR1
SCHEMBL19970810 0.92 CHEK2 (0.41) SLC2A1KCNH2FGFR1FLT1DGAT1
SCHEMBL19970854 0.92 MAOB (0.48) SLC2A1KCNH2HDAC6DGAT1GNRHR
SCHEMBL23843058 0.90 CHEK2 (0.43) SLC2A1KCNH2DGAT1SOAT1
SCHEMBL19982583 0.89 SLC2A1 (0.42) SLC2A1KCNH2HDAC6FGFR1FLT1
SCHEMBL19982564 0.87 SLC2A1 (0.42) SLC2A1NPBWR1
SCHEMBL19970850 0.86 GNRHR (0.47) SLC2A1HDAC6GNRHRTACR2HRH2
SCHEMBL19982579 0.85 SLC2A1 (0.44) SLC2A1KCNH2HDAC6FGFR1FLT1
SCHEMBL19970804 0.85 CNR2 (0.40) SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
WO-2018050771-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-22 WO disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION FIP1L1, ZC3HAV1, MAVS SLC2A1 4852/4885KCNH2 2042/4885HDAC6 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.